statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR, the Company), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated...

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September...

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. (Exicure or the Company) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the Staff Delisting Determination) from the Listing Qualifications Department...

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In...

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. (Exicure or the Company) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (Nasdaq) on April 17, 2024 notifying the Company that, as a...

Exicure and Bluejay sign hepatitis treatment development deal

Under the deal terms, Bluejay will have the sole licence to Exicure's patents relevant to hepatitis. Bluejay made an initial payment to Exicure following the deal execution. In
The post Exicure and...

Exicure, Bluejay Therapeutics enter into patent license pact

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and...

Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR  Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 821,100 shares, a growth of 495.9% from the...

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Volume	1.06M
52-Wk High	$1.12
52-Wk Low	$0.2914

XCUR Exicure Inc

About

Feed

News

Fundamentals